Transgene SA (OTCMKTS:TRGNF – Get Free Report) shares dropped 7.4% during mid-day trading on Wednesday . The stock traded as low as $1.00 and last traded at $1.00. Approximately 500 shares traded hands during trading, an increase of 15% from the average daily volume of 433 shares. The stock had previously closed at $1.08.
Transgene Stock Down 7.4%
The company’s 50 day moving average price is $0.71 and its 200 day moving average price is $0.70.
About Transgene
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase I clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of gastrointestinal and colorectal cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors.
Recommended Stories
- Five stocks we like better than Transgene
- ETF Screener: Uses and Step-by-Step Guide
- 3 Stocks Poised to Benefit From Google’s AI Breakthough
- What Are Some of the Best Large-Cap Stocks to Buy?
- Beyond NVIDIA: 5 Semiconductor Stocks Set to Dominate 2026
- 5 discounted opportunities for dividend growth investors
- 3 Stocks You’ll Wish You Bought Before 2026
Receive News & Ratings for Transgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transgene and related companies with MarketBeat.com's FREE daily email newsletter.
